Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > Articoli online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 Nov 18


Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413



The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 Nov 18

lingua: Inglese

Preclinical imaging in oncology: advances and perspectives

Francesca IOMMELLI 1, Viviana DE ROSA 1, Cristina TERLIZZI 2, Silvana DEL VECCHIO 2

1 Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy; 2 Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy


Preclinical imaging with radiolabeled probes became an integral part of the complex translational process that moves a newly developed compound from laboratory to clinical application. Imaging studies in animal tumor models may be undertaken to test a newly synthesized tracer, a newly developed drug or to interrogate, in the living organism, specific molecular and biological processes underlying tumor growth and progression. The present review will try to delineate the current status and future perspectives of preclinical imaging in oncology by providing examples from recent literature. Among the biological processes and molecular targets that can be visualized with radiolabeled probes in animal tumor models, we focused on proliferation, expression of targets suitable for therapy, glycolytic phenotype, metastatic dissemination, tumor angiogenesis and survival. The major contribution of preclinical imaging emerging from these studies is the development and validation of imaging biomarkers that can be translated into the clinical context for patient selection and evaluation of tumor response to molecularly targeted agents.

inizio pagina